Human Chorionic Gonadotropin Market Size & Growth Analysis to 2030

The global human chorionic gonadotropin market size is projected to grow at the CAGR of 7.1% market during 2020-2027. For the treatment of infertility in both men and women the human chorionic gonadotropin drugs are used. Rising prevalence of infertility, increased maternity age, lifestyle effects, hormonal dysfunctions in both men and women, and growing demand for the hormonal drug therapy are the key factors that have propelled the growth for HCG drugs in the market. Even though newer assisted techniques such as in-vitro fertilization have been well developed, HCG drugs are still the first choice for treatment of infertility. Since the human body is chiefly regulated by hormones, infertility is caused due to abnormal hormone secretion and hence there is great demand for the hormonal drug therapy.

Market Insights:

Increasing prevalence of infertility which requires the use of human chorionic gonadotropin for its treatment and the demand for hormonal drug therapy are the key trends which are witnessed in the human chorionic gonadotropin market. In 2019, female infertility treatment held the largest market share in the therapeutic area segment due to factors such as growing incidence of infertility in women, contributed by increased maternity age and lifestyle effects. However, in 2019, the technology market is segmented into (natural source extraction and recombinant DNA technology), Equal safety and efficacy of recombinant HCG in comparison to natural source HCG are the key driving factors that lead to higher demand for recombinant HCG in the global market. The human chorionic gonadotropin market is currently dominated by North America due to increasing prevalence of infertility, rising demand for hormonal drug therapy due to its safety and efficacy in comparison to synthetic drugs, supportive reimbursement policies and advanced healthcare infrastructure.

Market Segment Insights:

The global human chorionic gonadotropin market is segmented by therapeutic area such as (female infertility treatment, oligospermia treatment, cryptorchidism treatment and others); this segment is dominated by the female infertility treatment market mainly due to factors such as rising female infertility and growing public awareness. Technology segment consist of (natural source extraction and recombinant DNA technology); this segment is dominated by the recombinant DNA technology as it is safer and effective technique in comparison to natural source extraction, less impurities occur in the final HCG products etc.

Global Human Chorionic Gonadotropin Market Segmentation:

By Therapeutic Area, 2018–2027 ($ Million)

• Female Infertility Treatment
• Oligospermia Treatment
• Cryptorchidism Treatment
• Others

By Technology, 2018–2027 ($ Million)

• Natural Source Extraction
• Recombinant DNA Technology

By Geography, 2018-2027 ($ Million)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa and Asia Pacific, markets together form the major regional markets for human chorionic gonadotropin drugs. These regional markets are further sub-segmented into country specific markets on the basis of demand and market growth for HCG drugs. Among the considered regional markets, North America currently dominates the global human chorionic gonadotropin market, with United Sates being the largest county-level market. Increase in prevalence of infertility, higher public awareness, existence of advanced healthcare infrastructure and supportive reimbursement policies. On the other hand, Asia Pacific is anticipated to be the fastest growing market for human chorionic gonadotropin, the driving factors are lucrative opportunities to manufacturers of human chorionic gonadotropin drugs, huge population base suffering from infertility and government initiative to promote medical tourism and healthcare infrastructure.

Market Competition Assessment:

Key players in the global human chorionic gonadotropin market are Bristol Mayer Squibb Company, EMD Serono, Inc. Ferring B.V., Fresenius Kabi USA, LLC and Merck & Co., Inc.

List of Key Companies:

• Bristol Mayer Squibb Company
• EMD Serono, Inc.
• Ferring B.V.
• Fresenius Kabi USA, LLC
• Merck & Co., Inc.

Key Questions Answered by Human Chorionic Gonadotropin (HCG) Market Report

• Global human chorionic gonadotropin (hcg) market forecasts from 2020-2027
• Regional human chorionic gonadotropin (hcg) market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country level forecasts from 2020-2027 covering 15 major countries from aforementioned regions
• Human Chorionic Gonadotropin (HCG) submarket forecasts from 2020-2027 covering the market by technology, by therapeutic area, and geography
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to human chorionic gonadotropin market
• Analysis of the key factors driving and restraining the growth of the global, regional and country level human chorionic gonadotropin markets from 2020-2027
• Competitive Landscape and market positioning of top 10 players operating in the human chorionic gonadotropin market

Request a full report sample to review @ https://www.researchcorridor.com/request-sample/?id=22042